Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGE-C2 TCR T-cell therapy with epigenetic treatment in advanced melanoma or HNSCC
NL-OMON60021Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous MAGE-C2-specific TCR T cells in melanoma and head and neck squamous cell carcinoma (HNSCC), sponsored by Erasmus MC. Primary endpoints: Adverse events, Recommended Phase II dose and 4 more. Started Nov 2024; status: recruiting.
02
Drugs
autologous MAGE-C2-specific TCR T cells
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON60021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60021.